Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1948 4
1949 5
1951 3
1952 5
1953 2
1954 5
1955 6
1956 5
1957 2
1958 8
1959 2
1961 9
1962 15
1963 16
1964 15
1965 18
1966 22
1967 31
1968 26
1969 39
1970 33
1971 21
1972 26
1973 24
1974 34
1975 33
1976 21
1977 21
1978 33
1979 38
1980 49
1981 53
1982 71
1983 79
1984 95
1985 104
1986 107
1987 111
1988 127
1989 139
1990 151
1991 150
1992 130
1993 124
1994 107
1995 141
1996 151
1997 168
1998 191
1999 204
2000 238
2001 205
2002 257
2003 272
2004 311
2005 324
2006 368
2007 386
2008 357
2009 398
2010 387
2011 448
2012 516
2013 512
2014 521
2015 552
2016 564
2017 619
2018 635
2019 626
2020 768
2021 954
2022 534
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

12,451 results
Results by year
Filters applied: . Clear all
Page 1
Profiling the inhibitory receptors LAG-3, TIM-3, and TIGIT in renal cell carcinoma reveals malignancy.
Takamatsu K, Tanaka N, Hakozaki K, Takahashi R, Teranishi Y, Murakami T, Kufukihara R, Niwa N, Mikami S, Shinojima T, Sasaki T, Sato Y, Kume H, Ogawa S, Kakimi K, Kamatani T, Miya F, Tsunoda T, Aimono E, Nishihara H, Sawada K, Imamura T, Mizuno R, Oya M. Takamatsu K, et al. Among authors: sato y. Nat Commun. 2021 Sep 20;12(1):5547. doi: 10.1038/s41467-021-25865-0. Nat Commun. 2021. PMID: 34545095 Free PMC article.
Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT).
Sakata Y, Sakata S, Oya Y, Tamiya M, Suzuki H, Shibaki R, Okada A, Kobe H, Matsumoto H, Yokoi T, Sato Y, Uenami T, Saito G, Tsukita Y, Inaba M, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Morinaga J, Sakagami T. Sakata Y, et al. Among authors: sato y. Eur J Cancer. 2021 Dec;159:144-153. doi: 10.1016/j.ejca.2021.09.041. Epub 2021 Nov 5. Eur J Cancer. 2021. PMID: 34749119
Reply.
Harada J, Nagata K, Morimoto T, Iwata K, Matsunashi A, Sato Y, Tachikawa R, Ishikawa A, Tomii K. Harada J, et al. Among authors: sato y. Respirology. 2022 Apr;27(4):318-319. doi: 10.1111/resp.14221. Epub 2022 Feb 2. Respirology. 2022. PMID: 35112437 Free article. No abstract available.
Efficacy and Safety of Ultrahigh-Dose Methylcobalamin in Early-Stage Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.
Oki R, Izumi Y, Fujita K, Miyamoto R, Nodera H, Sato Y, Sakaguchi S, Nokihara H, Kanai K, Tsunemi T, Hattori N, Hatanaka Y, Sonoo M, Atsuta N, Sobue G, Shimizu T, Shibuya K, Ikeda K, Kano O, Nishinaka K, Kojima Y, Oda M, Komai K, Kikuchi H, Kohara N, Urushitani M, Nakayama Y, Ito H, Nagai M, Nishiyama K, Kuzume D, Shimohama S, Shimohata T, Abe K, Ishihara T, Onodera O, Isose S, Araki N, Morita M, Noda K, Toda T, Maruyama H, Furuya H, Teramukai S, Kagimura T, Noma K, Yanagawa H, Kuwabara S, Kaji R; Japan Early-Stage Trial of Ultrahigh-Dose Methylcobalamin for ALS (JETALS) Collaborators. Oki R, et al. Among authors: sato y. JAMA Neurol. 2022 Jun 1;79(6):575-583. doi: 10.1001/jamaneurol.2022.0901. JAMA Neurol. 2022. PMID: 35532908 Clinical Trial.
CD153/CD30 signaling promotes age-dependent tertiary lymphoid tissue expansion and kidney injury.
Sato Y, Oguchi A, Fukushima Y, Masuda K, Toriu N, Taniguchi K, Yoshikawa T, Cui X, Kondo M, Hosoi T, Komidori S, Shimizu Y, Fujita H, Jiang L, Kong Y, Yamanashi T, Seita J, Yamamoto T, Toyokuni S, Hamazaki Y, Hattori M, Yoshikai Y, Boor P, Floege J, Kawamoto H, Murakawa Y, Minato N, Yanagita M. Sato Y, et al. J Clin Invest. 2022 Jan 18;132(2):e146071. doi: 10.1172/JCI146071. J Clin Invest. 2022. PMID: 34813503 Free PMC article.
Structure of the bile acid transporter and HBV receptor NTCP.
Asami J, Kimura KT, Fujita-Fujiharu Y, Ishida H, Zhang Z, Nomura Y, Liu K, Uemura T, Sato Y, Ono M, Yamamoto M, Noda T, Shigematsu H, Drew D, Iwata S, Shimizu T, Nomura N, Ohto U. Asami J, et al. Among authors: sato y. Nature. 2022 Jun;606(7916):1021-1026. doi: 10.1038/s41586-022-04845-4. Epub 2022 May 17. Nature. 2022. PMID: 35580629
Population pharmacokinetic modeling of GS-441524, the active metabolite of remdesivir, in Japanese COVID-19 patients with renal dysfunction.
Sukeishi A, Itohara K, Yonezawa A, Sato Y, Matsumura K, Katada Y, Nakagawa T, Hamada S, Tanabe N, Imoto E, Kai S, Hirai T, Yanagita M, Ohtsuru S, Terada T, Ito I. Sukeishi A, et al. Among authors: sato y. CPT Pharmacometrics Syst Pharmacol. 2022 Jan;11(1):94-103. doi: 10.1002/psp4.12736. Epub 2021 Nov 18. CPT Pharmacometrics Syst Pharmacol. 2022. PMID: 34793625 Free PMC article.
Drug-Related Pneumonitis Induced by Osimertinib as First-Line Treatment for Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer: A Real-World Setting.
Sato Y, Sumikawa H, Shibaki R, Morimoto T, Sakata Y, Oya Y, Tamiya M, Suzuki H, Matsumoto H, Yokoi T, Hashimoto K, Kobe H, Hino A, Inaba M, Tsukita Y, Ikeda H, Arai D, Maruyama H, Hara S, Tsumura S, Sakata S, Fujimoto D. Sato Y, et al. Chest. 2022 Jun 1:S0012-3692(22)01068-6. doi: 10.1016/j.chest.2022.05.035. Online ahead of print. Chest. 2022. PMID: 35661746
First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in advanced non-small cell lung cancer: a subanalysis of Asian patients in CheckMate 9LA.
John T, Sakai H, Ikeda S, Cheng Y, Kasahara K, Sato Y, Nakahara Y, Takeda M, Kaneda H, Zhang H, Maemondo M, Minato K, Hisada T, Misumi Y, Satouchi M, Hotta K, Li A, Oukessou A, Lu S. John T, et al. Among authors: sato y. Int J Clin Oncol. 2022 Apr;27(4):695-706. doi: 10.1007/s10147-022-02120-0. Epub 2022 Feb 19. Int J Clin Oncol. 2022. PMID: 35182247 Free PMC article. Clinical Trial.
12,451 results
You have reached the last available page of results. Please see the User Guide for more information.